Posttransplant cyclophosphamide versus anti‐thymocyte globulin versus combination for graft‐versus‐host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party
Cancer · 2024
DOI: 10.1002/cncr.35365 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer, 2024. Verfasst von Abdul-Hamid Bazarbachi und 15 weiteren Autor:innen. Beteiligte Einrichtung: EBMT Paris study office/CEREST-TC, Paris, France. Hauptthemen laut MEDLINE: Antilymphocyte Serum, Graft vs Host Disease, Cyclophosphamide, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
Background
The optimal choice for graft‐versus‐host disease (GVHD) prophylaxis in haploidentical stem cell transplantation (haplo‐SCT) remains debatable. Posttransplant cyclophosphamide (PTCy) and anti‐thymocyte globulin (ATG) are two common strategies, but little is known about their combination.
Methods
Using the European Society for Blood and Marrow Transplantation (EBMT) registry, the authors identified 3649 adult patients with acute myeloid leukemia (AML) who underwent haplo‐SCT in complete remission between 2007 and 2021 at 260 EBMT‐participating centers who received either PTCy ( n = 2999), ATG ( n = 358), or combination prophylaxis ( n = 292). Cord blood transplants, combined bone marrow and peripheral grafts, and transplants with ex vivo graft manipulation were excluded. Median follow‐up was 31.8 months.
Results
On multivariate analysis, adjusting for patient age and performance status, disease status at transplant, cytogenetic risk, conditioning intensity, stem cell source, female‐to‐male graft, and donor and patient CMV status, we present the following. Compared to PTCy, ATG had a higher risk of nonrelapse mortality (hazard ratio [HR], 1.6; p = .003), worse leukemia‐free survival (HR, 1.4; p = .002), overall survival (HR, 1.49; p = .0009), and GVHD‐free and relapse‐free survival (HR, 1.29; p = .012). The combination of PTCy and ATG, however, led to significantly reduced rates of grade 2–4 (HR, 0.51; p = .0003) and grade 3–4 (HR, 0.5; p = .018) acute GVHD and did not affect any transplant outcomes compared to PTCy without ATG.
Conclusion
The authors conclude that ATG alone is a less effective prophylaxis strategy compared to PTCy, however, the combination of PTCy and ATG is superior to either monotherapy. They propose that this combination could be considered a potential new standard of care for GVHD prophylaxis in haplo‐SCT for AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- EBMT Paris study office/CEREST-TC, Paris, France.
- Department of Hematology, Saint Antoine Hospital, Paris, France.
- INSERM UMR 938, Sorbonne University, Paris, France.
- Division of Hematology/Oncology, Columbia University Irving Medical Center/New York-Presbyterian Hospital, New York, New York, USA.
- Hematology and Cellular Therapy Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
- Transplantation and Cellular Immunotherapy Program, Department of Hematology, Institut Paoli Calmettes, MSC Lab, Aix Marseille University, Marseille, France.
ORCID-Profile: Abdul-Hamid Bazarbachi
Zitieren
APA
Bazarbachi, A. H., Labopin, M., Raiola, A. M., Blaise, D., Arcese, W., Santarone, S., Koc, Y., Bramanti, S., Kulagin, A., Kwon, M., Sica, S., Sanz, J., Brissot, E., Nagler, A., Ciceri, F., & Mohty, M. (2024). Posttransplant cyclophosphamide versus anti‐thymocyte globulin versus combination for graft‐versus‐host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Cancer. https://doi.org/10.1002/cncr.35365
Vancouver
Bazarbachi AH, Labopin M, Raiola AM, Blaise D, Arcese W, Santarone S, et al. Posttransplant cyclophosphamide versus anti‐thymocyte globulin versus combination for graft‐versus‐host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Cancer. 2024. doi:10.1002/cncr.35365
BibTeX
@article{Bazarbachi2024,
author = {Bazarbachi, Abdul-Hamid and Labopin, Myriam and Raiola, Anna Maria and Blaise, Didier and Arcese, William and Santarone, Stella and Koc, Yener and Bramanti, Stefania and Kulagin, Alexander and Kwon, Mi and Sica, Simona and Sanz, Jaime and Brissot, Eolia and Nagler, Arnon and Ciceri, Fabio and Mohty, Mohamad},
title = {Posttransplant cyclophosphamide versus anti‐thymocyte globulin versus combination for graft‐versus‐host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35365}
}
EUVIMED